CDKN2A and cancer: Patients with rare cancers more frequently had CDKN2A and BRAF genetic alterations compared to patients with non-rare cancers, leading to more matches with CDK4/6 inhibitors (14% vs. 4%; p ≤ 0.001) or BRAF inhibitors (9% vs. 1%; p ≤ 0.001).